DDInter305 DDInter1676
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Carvedilol {u} (Compound) resembles {v} (Compound) Propafenone
Carvedilol {u} (Compound) resembles {v} (Compound) Bopindolol
Carvedilol {u} (Compound) treats {v} (Disease) hypertension
Carvedilol {u} (Compound) binds {v} (Gene) CYP1A1
Carvedilol {u} (Compound) upregulates {v} (Gene) INSIG1
Carvedilol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta1-Antagonists
Carvedilol {u} (Compound) downregulates {v} (Gene) CDC20
Carvedilol {u} (Compound) causes {v} (Side Effect) Angina unstable
Carvedilol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kaolin
Carvedilol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Carvedilol (Compound) resembles Propafenone (Compound)
Carvedilol (Compound) resembles Bopindolol (Compound)
Carvedilol (Compound) treats hypertension (Disease)
Carvedilol (Compound) binds CYP1A1 (Gene)
Carvedilol (Compound) upregulates INSIG1 (Gene)
Carvedilol (Compound) is included by Adrenergic beta1-Antagonists (Pharmacologic Class)
Carvedilol (Compound) downregulates CDC20 (Gene)
Carvedilol (Compound) causes Angina unstable (Side Effect)
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Kaolin
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine